ReviewFrontiers in pharmacology2023
Pharmacological treatment and vaccines in monkeypox virus: a narrative review and bibliometric analysis.
Review in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 35 citations in OpenAlex.
- Review
- Rethinking mpox: epidemiology, clinical variants, diagnosis, and response.Osong public health and research perspectives · 2026Article
- Exploration of the protein and pharmacological landscape of monkeypox virus treatment: from entry point to end point.Molecular diversity · 2026Review
- Article
- Drug repurposing against viral infections (2020-2025): clinical trials, computational strategies, and therapeutic interventions.Inflammopharmacology · 2026Review
- Mpox in South Asia: A Narrative Review on Epidemiology, Preparedness, and Preventive Strategies.Health science reports · 2026Article
- The Emerging Threat of Monkeypox: An Updated Overview.Viruses · 2026Review
- First Comprehensive Global Bibliometric Analysis of Monkeypox Virus Research Landscape From 1976 to 2025.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Article
- Review
- Diagnostic Advances and Public Health Challenges for Monkeypox Virus: Clade-Specific Insight and the Urgent Need for Rapid Testing in Africa.Diagnostics (Basel, Switzerland) · 2025Review
- Re-emergence and clinical management of monkeypox: insights into viral biology, therapeutics, and vaccination.Molecular biology reports · 2025Review
- The Role of Public Health Interventions and Control Measures During Mpox Outbreaks: Enhancing Strategies for Disease Prevention and Management.Public health challenges · 2025Article
- Advancing the understanding and management of Mpox: insights into epidemiology, disease pathways, prevention, and therapeutic strategies.BMC infectious diseases · 2025Review
- Mapping Global Scientific Production on Human Immunodeficiency Virus and Monkeypox: A Scientometric Study.Health science reports · 2025Article
- Mpox treatment evolution: past milestones, present advances, and future directions.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Current status of next-generation vaccines against mpox virus: a scoping review.Frontiers in pharmacology · 2025Review
- Virology, epidemiology, transmissions, diagnostic tests, prophylaxis and treatments of human Mpox: Saudi Arabia perspective.Frontiers in cellular and infection microbiology · 2025Review
- Evaluating the advancements and efficacies in pharmacological Mpox treatments: a comprehensive review.Frontiers in pharmacology · 2025Review
- The Human Monkeypox Virus and Host Immunity: Emerging Diagnostic and Therapeutic Challenges.Infectious disorders drug targets · 2025Review
- Possible viral agents to consider in the differential diagnosis of blepharoconjunctivitis.World journal of virology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 13 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mpox (earlier known as monkeypox) virus infection is a recognized public health emergency. There has been little research on the treatment options. This article reviews the specific drugs used to treat mpox virus infection and the vaccines used here. Instead of focusing on the mechanistic basis, this review narrates the practical, real-life experiences of individual patients of mpox virus disease being administered these medicines. We conducted a bibliometric analysis on the treatment of the mpox virus using data from several databases like PubMed, Scopus, and Embase. The research on this topic has grown tremendously recently but it is highly concentrated in a few countries. Cidofovir is the most studied drug. This is because it is indicated and also used off-label for several conditions. The drugs used for mpox virus infection include tecovirimat, cidofovir, brincidofovir, vaccinia immune globulin, and trifluridine. Tecovirimat is used most frequently. It is a promising option in progressive mpox disease in terms of both efficacy and safety. Brincidofovir has been associated with treatment discontinuation due to elevated hepatic enzymes. Cidofovir is also not the preferred drug, often used because of the unavailability of tecovirimat. Trifluridine is used topically as an add-on agent along with tecovirimat for ocular manifestations of mpox virus disease. No study reports individual patient data for vaccinia immune globulin. Though no vaccine is currently approved for mpox virus infection, ACAM 2000 and JYNNEOS are the vaccines being mainly considered. ACAM 2000 is capable of replicating and may cause severe adverse reactions. It is used when JYNNEOS is contraindicated. Several drugs and vaccines are under development and have been discussed alongside pragmatic aspects of mpox virus treatment and prevention. Further studies can provide more insight into the safety and efficacy of Tecovirimat in actively progressing mpox virus disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.